Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-207907
- Development stage
- Phase 2
- Lead developer
- HK inno.N Corporation
01
Overview
IN-207907 is a drug candidate currently in the preclinical stage of development by **HK inno.N** (formerly known as CJ HealthCare) for the treatment of **sarcopenia**. Sarcopenia is a geriatric syndrome characterized by the progressive and generalized loss of skeletal muscle mass and strength, which correlates with physical disability and poor quality of life. While IN-207907 is featured in the company's R&D pipeline for degenerative diseases, specific details regarding its molecular target, chemical modality (such as small molecule or biologic), and exact mechanism of action have not yet been publicly disclosed.
Beyond the preview
Go deeper on IN-207907.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-207907.